Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free VRAX Stock Alerts

Virax Biolabs Group (VRAX) Competitors

Virax Biolabs Group logo
$2.56 +0.01 (+0.39%)
As of 04:00 PM Eastern
Compare

VRAX vs. ICCM, NVNO, NXL, INBS, and NDRA

Should you buy Virax Biolabs Group stock or one of its competitors? Virax Biolabs Group's main competitors and comparable companies include IceCure Medical (ICCM), enVVeno Medical (NVNO), Nexalin Technology (NXL), Intelligent Bio Solutions (INBS), and ENDRA Life Sciences (NDRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Virax Biolabs Group compare to IceCure Medical?

IceCure Medical (NASDAQ:ICCM) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.

IceCure Medical presently has a consensus price target of $52.50, suggesting a potential upside of 2,286.36%. Virax Biolabs Group has a consensus price target of $25.00, suggesting a potential upside of 876.56%. Given IceCure Medical's stronger consensus rating and higher probable upside, analysts plainly believe IceCure Medical is more favorable than Virax Biolabs Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IceCure Medical
2 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.20
Virax Biolabs Group
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

0.6% of IceCure Medical shares are held by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are held by institutional investors. 2.4% of IceCure Medical shares are held by insiders. Comparatively, 45.1% of Virax Biolabs Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Virax Biolabs Group has a net margin of 0.00% compared to IceCure Medical's net margin of -427.67%. Virax Biolabs Group's return on equity of 0.00% beat IceCure Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
IceCure Medical-427.67% -174.26% -112.58%
Virax Biolabs Group N/A N/A N/A

IceCure Medical has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market. Comparatively, Virax Biolabs Group has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market.

Virax Biolabs Group has lower revenue, but higher earnings than IceCure Medical.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IceCure Medical$3.38M2.23-$15.06M-$8.52N/A
Virax Biolabs Group$10K204.80-$5.02MN/AN/A

In the previous week, IceCure Medical's average media sentiment score of 0.00 equaled Virax Biolabs Group'saverage media sentiment score.

Company Overall Sentiment
IceCure Medical Neutral
Virax Biolabs Group Neutral

Summary

Virax Biolabs Group beats IceCure Medical on 8 of the 12 factors compared between the two stocks.

How does Virax Biolabs Group compare to enVVeno Medical?

enVVeno Medical (NASDAQ:NVNO) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

enVVeno Medical has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market. Comparatively, Virax Biolabs Group has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market.

Virax Biolabs Group has higher revenue and earnings than enVVeno Medical.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
enVVeno MedicalN/AN/A-$19.47M-$19.33N/A
Virax Biolabs Group$10K204.80-$5.02MN/AN/A

Virax Biolabs Group's return on equity of 0.00% beat enVVeno Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
enVVeno MedicalN/A -62.28% -56.83%
Virax Biolabs Group N/A N/A N/A

Virax Biolabs Group has a consensus target price of $25.00, suggesting a potential upside of 876.56%. Given Virax Biolabs Group's higher probable upside, analysts plainly believe Virax Biolabs Group is more favorable than enVVeno Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
enVVeno Medical
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.33
Virax Biolabs Group
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

34.7% of enVVeno Medical shares are owned by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are owned by institutional investors. 15.0% of enVVeno Medical shares are owned by company insiders. Comparatively, 45.1% of Virax Biolabs Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, enVVeno Medical's average media sentiment score of 0.00 equaled Virax Biolabs Group'saverage media sentiment score.

Company Overall Sentiment
enVVeno Medical Neutral
Virax Biolabs Group Neutral

Summary

Virax Biolabs Group beats enVVeno Medical on 8 of the 11 factors compared between the two stocks.

How does Virax Biolabs Group compare to Nexalin Technology?

Nexalin Technology (NASDAQ:NXL) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

Virax Biolabs Group has a net margin of 0.00% compared to Nexalin Technology's net margin of -4,141.94%. Virax Biolabs Group's return on equity of 0.00% beat Nexalin Technology's return on equity.

Company Net Margins Return on Equity Return on Assets
Nexalin Technology-4,141.94% -278.24% -218.42%
Virax Biolabs Group N/A N/A N/A

Virax Biolabs Group has a consensus price target of $25.00, suggesting a potential upside of 876.56%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, analysts plainly believe Virax Biolabs Group is more favorable than Nexalin Technology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nexalin Technology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Virax Biolabs Group
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Virax Biolabs Group has lower revenue, but higher earnings than Nexalin Technology.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nexalin Technology$300K13.04-$8.22M-$14.41N/A
Virax Biolabs Group$10K204.80-$5.02MN/AN/A

0.7% of Nexalin Technology shares are held by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are held by institutional investors. 16.9% of Nexalin Technology shares are held by insiders. Comparatively, 45.1% of Virax Biolabs Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Nexalin Technology has a beta of 3.95, indicating that its stock price is 295% more volatile than the broader market. Comparatively, Virax Biolabs Group has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market.

In the previous week, Nexalin Technology had 6 more articles in the media than Virax Biolabs Group. MarketBeat recorded 6 mentions for Nexalin Technology and 0 mentions for Virax Biolabs Group. Virax Biolabs Group's average media sentiment score of 0.00 beat Nexalin Technology's score of 0.00 indicating that Virax Biolabs Group is being referred to more favorably in the news media.

Company Overall Sentiment
Nexalin Technology Neutral
Virax Biolabs Group Neutral

Summary

Virax Biolabs Group beats Nexalin Technology on 11 of the 14 factors compared between the two stocks.

How does Virax Biolabs Group compare to Intelligent Bio Solutions?

Intelligent Bio Solutions (NASDAQ:INBS) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

Virax Biolabs Group has a consensus price target of $25.00, indicating a potential upside of 876.56%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, analysts plainly believe Virax Biolabs Group is more favorable than Intelligent Bio Solutions.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intelligent Bio Solutions
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Virax Biolabs Group
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Virax Biolabs Group has lower revenue, but higher earnings than Intelligent Bio Solutions.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intelligent Bio Solutions$4.22M1.65-$12.43M-$9.02N/A
Virax Biolabs Group$10K204.80-$5.02MN/AN/A

33.0% of Intelligent Bio Solutions shares are held by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are held by institutional investors. 1.3% of Intelligent Bio Solutions shares are held by company insiders. Comparatively, 45.1% of Virax Biolabs Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Virax Biolabs Group has a net margin of 0.00% compared to Intelligent Bio Solutions' net margin of -294.88%. Virax Biolabs Group's return on equity of 0.00% beat Intelligent Bio Solutions' return on equity.

Company Net Margins Return on Equity Return on Assets
Intelligent Bio Solutions-294.88% -175.35% -91.25%
Virax Biolabs Group N/A N/A N/A

Intelligent Bio Solutions has a beta of 4.25, indicating that its stock price is 325% more volatile than the broader market. Comparatively, Virax Biolabs Group has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market.

In the previous week, Intelligent Bio Solutions had 3 more articles in the media than Virax Biolabs Group. MarketBeat recorded 3 mentions for Intelligent Bio Solutions and 0 mentions for Virax Biolabs Group. Intelligent Bio Solutions' average media sentiment score of 0.31 beat Virax Biolabs Group's score of 0.00 indicating that Intelligent Bio Solutions is being referred to more favorably in the media.

Company Overall Sentiment
Intelligent Bio Solutions Neutral
Virax Biolabs Group Neutral

Summary

Virax Biolabs Group beats Intelligent Bio Solutions on 9 of the 14 factors compared between the two stocks.

How does Virax Biolabs Group compare to ENDRA Life Sciences?

Virax Biolabs Group (NASDAQ:VRAX) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

Virax Biolabs Group currently has a consensus price target of $25.00, indicating a potential upside of 876.56%. ENDRA Life Sciences has a consensus price target of $25.00, indicating a potential upside of 340.14%. Given Virax Biolabs Group's higher probable upside, research analysts plainly believe Virax Biolabs Group is more favorable than ENDRA Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Virax Biolabs Group
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
ENDRA Life Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Virax Biolabs Group has higher revenue and earnings than ENDRA Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virax Biolabs Group$10K204.80-$5.02MN/AN/A
ENDRA Life SciencesN/AN/A-$7.03M-$6.38N/A

8.6% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Virax Biolabs Group's return on equity of 0.00% beat ENDRA Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Virax Biolabs GroupN/A N/A N/A
ENDRA Life Sciences N/A -246.34%-150.81%

Virax Biolabs Group has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.05, indicating that its share price is 105% less volatile than the broader market.

In the previous week, Virax Biolabs Group's average media sentiment score of 0.00 equaled ENDRA Life Sciences'average media sentiment score.

Company Overall Sentiment
Virax Biolabs Group Neutral
ENDRA Life Sciences Neutral

Summary

Virax Biolabs Group beats ENDRA Life Sciences on 8 of the 8 factors compared between the two stocks.

Get Virax Biolabs Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRAX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRAX vs. The Competition

Export
MetricVirax Biolabs GroupHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2.03M$5.81B$7.26B$12.73B
Dividend YieldN/A1.76%2.53%8.86%
P/E RatioN/A25.93273.2825.38
Price / Sales204.8073.29613.4892.60
Price / CashN/A33.1477.8252.26
Price / Book0.066.0412.896.14
Net Income-$5.02M$150.03M$3.47B$349.01M
7 Day Performance-12.93%-1.29%-0.33%-1.47%
1 Month Performance-12.93%3.24%6.51%2.47%
1 Year Performance-83.06%7.42%25.19%15.84%

Virax Biolabs Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRAX
Virax Biolabs Group
2.3201 of 5 stars		$2.56
+0.4%		$25.00
+876.6%		-82.1%$2.03M$10KN/A5
ICCM
IceCure Medical
1.944 of 5 stars		$2.29
+0.4%		$52.50
+2,192.6%		-93.0%$7.81M$3.38MN/A60
NVNO
enVVeno Medical
1.3724 of 5 stars		$11.47
+6.2%		N/A-60.2%$7.50MN/AN/A30
NXL
Nexalin Technology
0.4701 of 5 stars		$0.30
-7.4%		N/A-78.1%$7.16M$300KN/A3
INBS
Intelligent Bio Solutions
0.9811 of 5 stars		$2.26
-4.2%		N/A-84.5%$7.14M$4.22MN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:VRAX) was last updated on 9/3/2026 by MarketBeat.com Staff.
From Our Partners
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel
Bezos… DOOMED
A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...
Paradigm Press | Sponsoredtc pixel